Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 47,276 leprosy patients cured by or released from WHO-recommended multidrug therapy (WHO/MDT). The overall relapse rate was 0.73/1000 patient-years (PY). There was a statistically significant difference in the relapse rates of WHO/MDT-MB (0.61/1000 PY) and WHO/MDT-PB (1.04/1000 PY) (chi 2 = 15.7, p < 0.01) patients. For multibacillary (MB) patients, the relapse rate in patients treated with fixed-duration MDT (0.56/1000 PY) was comparable with that in patients treated with MDT until skin-smear negativity (0.73/1000 PY) (chi 2 = 2.20, p > 0.05). Our present study suggests that fixed-duration MDT is a cost-effective regimen for the treatment of leprosy in China. The present results also show that relapse of leprosy is acceptably low and has not yet become a serious clinical or public health problem but, based upon the incubation of relapse in MDT patients, it is necessary to encourage annual follow up for at least 5 years for paucibacillary (PB) and 10 years for MB patients after being released from WHO/MDT.
Chen
X S
XS
Department for Leprosy Research, Chinese Academy of Medical Sciences, Nanjing, China. epicams@jlonline.com
Li
W Z
WZ
Jiang
C
C
Ye
G Y
GY
D002681:China; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000517:prevention & control*; D009313:National Health Programs / Q000706:statistics & numerical data*; D012008:Recurrence; D012307:Risk Factors; D014944:World Health Organization
D007917:Leprostatic Agents